Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“ASCO25, ATOMIC trial
In stage III dMMR colon cancer, adding atezolizumab to FOLFOX
Cut recurrence by 50%
3-yr DFS: 86.4% vs 76.6%
HR: 0.50
Could this approach also benefit patients with high-risk stage II colon cancer?”
Title: Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC)
Authors: Frank A. Sinicrope, Fang-Shu Ou, Tyler Zemla, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, Asha R. Dhanarajan, Christopher Hanyoung Lieu, Deirdre Jill Cohen, Federico Innocenti, Robert J. Behrens, Walter Peters, Nicolas Sommer, Eileen Mary O’Reilly, and Jeffrey A. Meyerhardt
Read the Full Article.
